Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at Stifel Nicolaus from $79.00 to $90.00. They now have a "buy" rating on the stock.
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $83.00 price target on the stock.
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]
Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Disc Medicine, Inc. (NASDAQ: IRON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $118.00 price target on the stock.